Melbourne, Australia, 11 October 2021: Certa Therapeutic, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
Certa Therapeutics is strengthening their senior leadership team with the appointment of Dr Lorna Mitchell as VP, Drug Discovery and Pharmacology.
Certa Therapeutics is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrosis diseases.
Dr Mitchell is a medicinal chemist with over 20 years of international drug discovery experience. She has a PhD in organic chemistry from the University of Auckland and completed her postdoctoral studies at the University of Rochester in New York.
Dr Mitchell is an inventor on over 40 patents and has been directly involved in the delivery of 10 drug candidates to the clinic. She spent the first 10 years of her industry career at Pfizer working at sites in both the USA and the UK. Following this large Pharma experience, Dr Mitchell spent seven years working in oncology focused biotech’s in Boston, including four years at Epizyme.
“We are delighted to appoint Dr Mitchell to lead our drug discovery and pharmacology program. She comes to Certa with experience across a range of therapeutic areas including oncology, CNS, dermatology, antivirals, inflammation, and inhalation. Dr Mitchell will be a valuable asset to our growing team,” says Professor Darren Kelly, Chief Executive Officer of Certa Therapeutics.